CLSD

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Clearside Biomedical (CLSD - Research Report) today and set a price target of $6.00. The company's shares closed yesterday at $1.28.According to TipRanks, Chen is an analyst with an average return of -26.0% and a 25.82% success rate. Chen covers the Healthcare sector, focusing on stocks such as Veru, Applied DNA Sciences, and Aslan Pharmaceuticals.Currently, the analyst consensus on Clearside Biomedical is a Moderate Buy with an average price target of $6.50, which is a 407.81% upside from current levels. In a report released yesterday, JMP Securities also reiterated a Buy rating on the stock with a $7.00 price target.
https://www.tipranks.com/news/blurbs/clearside-biomedical-clsd-gets-a-buy-from-h-c-wainwright-2?utm_source=advfn.com&utm_medium=referral